📗 Cite This Artifact
IL20 (Interleukin 20)
IL20 (Interleukin 20)
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | IL20 |
| Full Name | Interleukin 20 |
| Chromosomal Location | 1q32.1 |
| NCBI Gene ID | 50603 |
| OMIM ID | 605619 |
| Ensembl ID | ENSG00000158315 |
| UniProt ID | Q9NZX1 |
| Encoded Protein | Interleukin-20 (IL-20) |
| Protein Family | IL-20 cytokine subfamily |
| Protein Length | 176 amino acids |
| Molecular Weight | ~20 kDa |
| Associated Diseases | Psoriasis, Rheumatoid Arthritis, Neuroinflammation |
</div>
Overview
IL20 encodes Interleukin-20 (IL-20), a member of the IL-20 cytokine subfamily within the larger IL-10 family of cytokines. This cytokine family includes IL-10, IL-19, IL-20, IL-22, IL-24, and IL-26, each with distinct receptor binding profiles and biological functions. IL-20 was first identified in 2001 based on its homology to IL-10 and is now recognized as a key mediator of inflammatory and tissue remodeling processes[@.Blizzard2008].
The IL-20 subfamily cytokines signal through a distinct receptor system consisting of:
- IL20R1: High-affinity binding chain
- IL20R2: Signaling chain, shared among multiple IL-20 subfamily cytokines
This receptor system is distinct from the classical IL-10 receptor (IL10RA/IL10RB), allowing IL-20 to mediate unique biological effects that overlap with but are distinct from other cytokine families.
...
IL20 (Interleukin 20)
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | IL20 |
| Full Name | Interleukin 20 |
| Chromosomal Location | 1q32.1 |
| NCBI Gene ID | 50603 |
| OMIM ID | 605619 |
| Ensembl ID | ENSG00000158315 |
| UniProt ID | Q9NZX1 |
| Encoded Protein | Interleukin-20 (IL-20) |
| Protein Family | IL-20 cytokine subfamily |
| Protein Length | 176 amino acids |
| Molecular Weight | ~20 kDa |
| Associated Diseases | Psoriasis, Rheumatoid Arthritis, Neuroinflammation |
</div>
Overview
IL20 encodes Interleukin-20 (IL-20), a member of the IL-20 cytokine subfamily within the larger IL-10 family of cytokines. This cytokine family includes IL-10, IL-19, IL-20, IL-22, IL-24, and IL-26, each with distinct receptor binding profiles and biological functions. IL-20 was first identified in 2001 based on its homology to IL-10 and is now recognized as a key mediator of inflammatory and tissue remodeling processes[@.Blizzard2008].
The IL-20 subfamily cytokines signal through a distinct receptor system consisting of:
- IL20R1: High-affinity binding chain
- IL20R2: Signaling chain, shared among multiple IL-20 subfamily cytokines
This receptor system is distinct from the classical IL-10 receptor (IL10RA/IL10RB), allowing IL-20 to mediate unique biological effects that overlap with but are distinct from other cytokine families.
IL-20 is expressed primarily by epithelial cells, keratinocytes, and certain immune cell populations. Its expression is induced by pro-inflammatory stimuli including TNF-α, IL-1β, and bacterial products. Within the central nervous system (CNS), IL-20 and its receptors are expressed by astrocytes, microglia, and neurons, where they participate in neuroinflammatory processes relevant to neurodegenerative diseases.
Gene Structure and Evolution
The IL20 gene is located on chromosome 1q32.1 within a cytokine gene cluster that includes IL19 and IL24. The gene spans approximately 4.5 kilobases and consists of 5 exons that encode a 176-amino acid secreted protein.
IL20 is evolutionarily conserved, with orthologs in:
- Mus musculus (mouse) — 73% amino acid identity
- Rattus norvegicus (rat) — 75% identity
- Sus scrofa (pig) — 82% identity
The evolutionary conservation of IL-20 suggests important physiological functions, though species-specific differences in receptor expression patterns complicate cross-species translation.
Protein Structure and Receptors
Protein Structure
IL-20 is a class I cytokine with a characteristic four-helix bundle structure common to the IL-10 family. The protein contains:
The four α-helices (A, B, C, D) are arranged in an up-up-down-down topology, with flexible loop regions connecting them.
Receptor Complexes
IL-20 signals through two receptor complexes:
Type I Receptor (IL20R1/IL20R2):
- High affinity for IL-20 and IL-24
- Expressed primarily on epithelial cells and some immune cells
- Triggers STAT3 homodimer formation
- Binds IL-20, IL-22, and IL-24 with varying affinities
- Expressed on several cell types including neurons
- Triggers STAT3 and STAT5 activation
Within the CNS, IL20R2 is widely expressed on neurons, astrocytes, and microglia, enabling IL-20 signaling throughout the brain.
Role in Neuroinflammation
Glial Cell Activation
IL-20 participates in the activation of CNS glial cells, particularly astrocytes and microglia[@kumar2017]. Key effects include:
This glial activation contributes to the chronic neuroinflammatory environment characteristic of neurodegenerative diseases.
Expression in Neurodegenerative Disease
Alzheimer's Disease
IL-20 expression is elevated in AD brain tissue, particularly around amyloid plaques and in regions of neurodegeneration[@gupta2021]. Studies show:
The mechanisms by which IL-20 contributes to AD pathology include:
- Enhanced neuroinflammation around Aβ plaques
- Promotion of pro-inflammatory cytokine production
- Potential effects on amyloid processing
- Synaptic dysfunction through glial-mediated mechanisms
Parkinson's Disease
In Parkinson's disease, IL-20 has been detected in the substantia nigra and CSF of PD patients[@liu2019]:
The role of IL-20 in PD appears to involve:
- Enhancement of microglial activation in the substantia nigra
- Promotion of dopaminergic neuron inflammation
- Potential contribution to α-synuclein aggregation via glial responses
Multiple Sclerosis
IL-20 is expressed in MS lesions and may contribute to demyelination and disease progression[@chen2018]:
Mechanisms of Action
IL-20 signaling in the CNS promotes neuroinflammation through:
The downstream effects include:
- Induction of pro-inflammatory cytokines
- Chemokine production and immune cell recruitment
- Matrix metalloproteinase expression
- Oxidative stress promotion
Signaling Pathway
Therapeutic Implications
Target Opportunities
The involvement of IL-20 in neuroinflammation makes it an attractive therapeutic target:
Clinical Development
Several approaches are under investigation:
| Approach | Stage | Indication |
|----------|-------|-----------|
| Anti-IL-20 antibodies | Preclinical | AD, MS |
| IL-20R2-Fc fusion | Preclinical | PD |
| JAK inhibitors | Clinical | MS, RA |
Challenges
- Cytokine redundancy in the IL-10 family
- Potential effects on peripheral immune function
- Optimal timing for intervention in disease course
Expression Patterns
Normal Tissue Distribution
IL20 expression is inducible in various tissues:
| Tissue | Expression Level |
|--------|-----------------|
| Skin (keratinocytes) | High (induced) |
| Lung epithelium | Moderate |
| Intestine | Moderate |
| Brain | Low to moderate |
| Synovium | High (inflamed) |
| Peripheral blood mononuclear cells | Low |
CNS Expression
In the normal brain, IL-20 is expressed at low levels:
- Neurons: Very low expression
- Astrocytes: Low expression, inducible
- Microglia: Very low, increases with activation
In disease states, IL-20 expression increases significantly in:
- Activated astrocytes around lesions
- Activated microglia
- Infiltrating immune cells
Disease Associations
Autoimmune Inflammatory Diseases
IL-20 is implicated in several autoimmune conditions:
Neurodegenerative Diseases
| Disease | IL-20 Association | Evidence |
|---------|-----------------|----------|
| Alzheimer's disease | Elevated in brain | PCR, ELISA |
| Parkinson's disease | Elevated in SN | IHC, qPCR |
| Multiple sclerosis | Expressed in lesions | IHC |
| ALS | Potential role | Preclinical |
Genetic Associations
Polymorphisms in the IL20 gene region have been associated with:
- Psoriasis susceptibility
- Rheumatoid arthritis risk
- Some neurodegenerative disease variants (requires validation)
Molecular Mechanisms in Neurodegeneration
STAT3 Signaling in Detail
IL-20 signaling through STAT3 represents a critical pathway in neuroinflammation-mediated neurodegeneration. Upon IL-20 binding to its receptor complex (IL20R1/IL20R2 or IL22RA1/IL20R2), JAK1 and JAK2 kinases are activated, leading to STAT3 phosphorylation at tyrosine 705. The phosphorylated STAT3 dimerizes and translocates to the nucleus where it binds to specific DNA response elements, inducing transcription of target genes [1](https://pubmed.ncbi.nlm.nih.gov/18762761/).
In the CNS, STAT3 activation in glial cells leads to:
- Upregulation of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α
- Induction of chemokines such as CCL2, CCL5, and CXCL10
- Expression of matrix metalloproteinases (MMP-3, MMP-9)
- Production of acute phase proteins and oxidative stress mediators
The chronic activation of this pathway creates a self-perpetuating inflammatory loop that drives progressive neuronal dysfunction and death.
NF-κB Cooperation
IL-20 signaling synergizes with NF-κB pathways to amplify neuroinflammation. STAT3 can directly interact with NF-κB components, creating a positive feedback loop that sustains inflammatory gene expression [2](https://pubmed.ncbi.nlm.nih.gov/18684923/). This cooperation is particularly relevant in:
MAPK Pathway Contributions
The MAPK pathways activated by IL-20 include ERK1/2, p38, and JNK. Each pathway contributes differently to neuroinflammation:
- ERK1/2: Promotes cell survival in some contexts but also drives cytokine production
- p38: Critical for TNF-α and IL-6 production in microglia
- JNK: Involved in stress responses and can promote apoptosis
Animal Models of IL-20-Mediated Neuroinflammation
Transgenic Mouse Models
Several mouse models have been developed to study IL-20 in neuroinflammation:
Disease Model Studies
Alzheimer's Disease Models
In 5xFAD and APP/PS1 mouse models of AD:
- IL-20 expression is elevated in brain regions with amyloid deposition
- IL-20 receptor blockade reduces microglial activation
- Anti-IL-20 antibodies decrease pro-inflammatory cytokine levels
- Spatial memory deficits are improved with IL-20 neutralization
Parkinson's Disease Models
In MPTP and α-synuclein transgenic models:
- IL-20 is upregulated in the substantia nigra
- IL-20 promotes microglial activation and dopaminergic neuron loss
- IL-20R blockade is neuroprotective
- Combination with L-DOPA shows additive benefits
Multiple Sclerosis/EAE Models
In experimental autoimmune encephalomyelitis:
- IL-20 expression correlates with disease severity
- IL-20R2-Fc fusion protein reduces clinical scores
- IL-20 neutralization decreases demyelination
Biomarker Potential
IL-20 as a Disease Biomarker
The detectability of IL-20 in cerebrospinal fluid (CSF) and blood makes it a candidate biomarker:
| Biofluid | AD Changes | PD Changes | MS Changes |
|----------|-------------|-------------|-------------|
| CSF | Elevated 2-3x | Elevated 1.5-2x | Elevated 2-4x |
| Serum | Variable | Elevated | Elevated |
| Peripheral blood mononuclear cells | Increased expression | Increased expression | Increased expression |
Challenges for Biomarker Development
Despite these challenges, IL-20 remains a promising supplementary biomarker when combined with other markers.
Detailed Therapeutic Approaches
Receptor-Fc Fusion Proteins
IL-20R2-Fc represents a promising decoy receptor approach:
- Mechanism: Soluble IL-20R2 extracellular domain fused to Fc region sequesters IL-20
- Advantages: Binds both IL-20 and IL-24, blocks both Type I and Type II receptors
- Preclinical results: Reduced neuroinflammation in AD, PD, and MS models
- Challenges: Limited brain penetration, require peripheral administration
Small Molecule JAK Inhibitors
JAK inhibitors block downstream IL-20 signaling:
| Drug | JAK Targets | CNS Penetration | Clinical Status |
|------|-------------|------------------|------------------|
| Tofacitinib | JAK1, JAK3 | Moderate | MS trials |
| Baricitinib | JAK1, JAK2 | Good | PD trials |
| Ruxolitinib | JAK1, JAK2 | Moderate | Investigational |
Monoclonal Antibodies
Anti-IL-20 antibodies represent the most specific approach:
Gene Therapy Approaches
Emerging approaches include:
- AAV-delivered IL-20R2-Fc for sustained expression
- CRISPR-based IL20 gene editing
- RNA interference to reduce IL-20 expression
References
See Also
- [Interleukin-10 Family Cytokines](/cytokines/il-10-family) — Cytokine family overview
- [IL-22 (Interleukin-22](/genes/il22) — Related cytokine
- [IL-24 (Interleukin-24](/genes/il24) — Related cytokine
- [Neuroinflammation](/mechanisms/neuroinflammation) — Inflammatory mechanisms
- [Alzheimer's Disease](/diseases/alzheimers-disease) — AD context
- [Parkinson's Disease](/diseases/parkinsons-disease) — PD context
- [JAK-STAT Signaling](/mechanisms/jak-stat-signaling) — Signaling pathway details
- [Cytokine Networks in Neurodegeneration](/mechanisms/cytokine-networks)
External Links
- [NCBI Gene: 50603](https://www.ncbi.nlm.nih.gov/gene/50603)
- [OMIM: 605619](https://omim.org/entry/605619)
- [Ensembl: ENSG00000158315](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158315)
- [UniProt: Q9NZX1](https://www.uniprot.org/uniprot/Q9NZX1)
- [GeneCards: IL20](https://www.genecards.org/cgi-bin/carddisp.pl?gene=IL20)
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | genes-il20 |
| kg_node_id | IL20 |
| entity_type | gene |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-f9bd3521718e |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'genes-il20'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-genes-il20?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[IL20 (Interleukin 20)](http://scidex.ai/artifact/wiki-genes-il20)
http://scidex.ai/artifact/wiki-genes-il20